The Zhitong Finance App learned that Cornerstone Pharmaceutical-B (02616) rose by more than 12%. As of press release, it had risen 12.73% to HK$1.24, with a turnover of HK$2.7634 million.

According to the news, the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting will be held in Chicago from May 31 to June 4, US Eastern Time, in a combination of online and offline formats. The conference is one of the most important conferences in the field of global oncology. Among the 2024 ASCO ADC key clinical trials inventoried by Guosheng Securities, Cornerstone Pharmaceutical CS5001 treated patients with advanced solid tumors and lymphoma, phase 1a/1b, and the first global multi-center human study.

Southwest Securities previously stated that CS5001 is a ROR1 ADC. Only three ROR1 ADCs are in the clinical phase. The first two models were acquired by MSD and Boehringer Ingelheim (BI) at a high price of $2.75 billion and $1.43 billion, respectively. The reason for this is that ROR1 is a tumor embryonic protein, which is highly expressed in various solid tumors and hematomas, such as non-small cell lung cancer, leukemia, lymphoma, etc. The global patient population is 3 million. Once the drug is developed, the space is expected to reach tens of billions of dollars.